Tolero Pharmaceuticals to Present at the Jefferies 2016 Global Healthcare Conference

SALT LAKE CITY–(BUSINESS WIRE)– Tolero
Pharmaceuticals, Inc., a clinical-stage pharmaceutical company
developing treatments for serious hematological diseases, announced
today that it will present at the Jefferies 2016 Global Healthcare
Conference taking place June 7-10, 2016 in New York City. David
J. Bearss, Ph.D., Chief Executive Officer, is scheduled to present
at 2:00 PM (EDT) and will answer questions in a breakout session at 2:30
PM (EDT) on Friday, June 10, 2016.

Tolero is currently initiating a multi-center randomized Phase 2
biomarker-driven clinical trial with their lead product alvocidib as
part of a regimen with cytarabine, and mitoxantrone in patients with
relapsed or refractory acute myeloid leukemia (AML) (clinicaltrials.gov
– NCT02520011). The trial will compare the above-referenced
alvocidib-containing regimen to cytarabine and mitoxantrone alone in a
biomarker-defined population of relapsed or refractory AML. The
biomarker is intended to identify patients with a dependency on the
cancer protein myeloid cell leukemia 1 (MCL-1). Alvocidib,
a cyclin-dependent kinase-9 (CDK9) inhibitor, blocks transcription of
MCL-1 and places AML cells in a heightened state of sensitivity to
apoptosis-inducing agents.

About Alvocidib
Alvocidib is a potent small-molecule inhibitor of
CDK9 in development as a combination therapy for frontline and
relapsed/refractory AML. CDK9 is a protein critical to the regulation of
gene expression including the MCL-1 gene and other important genes
involved in cancer. Given the key role CDK9 de-regulation plays in
expression of cancer-associated genes related to cell division and
proliferation, CDK9 is an attractive target for the treatment of various
cancers.

About Tolero
Tolero Pharmaceuticals is a clinical stage
biopharmaceutical company developing treatments to improve and extend
the lives of patients with serious oncological and hematological
diseases. Our diverse pipeline targets important biological drivers of
blood disorders to treat leukemias and anemia as well as important
targets of drug resistance and transcriptional control.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160606006271/en/